- Home
- CHI vs VIR Comparison
CHI vs VIR Comparison
Compare CHI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- VIR
- Stock Information
- Founded
- CHI 2002
- VIR 2016
- Country
- CHI United States
- VIR United States
- Employees
- CHI N/A
- VIR N/A
- Industry
- CHI Investment Managers
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- VIR Health Care
- Exchange
- CHI Nasdaq
- VIR Nasdaq
- Market Cap
- CHI 820.8M
- VIR 706.4M
- IPO Year
- CHI N/A
- VIR 2019
- Fundamental
- Price
- CHI $10.44
- VIR $5.65
- Analyst Decision
- CHI
- VIR Strong Buy
- Analyst Count
- CHI 0
- VIR 8
- Target Price
- CHI N/A
- VIR $30.25
- AVG Volume (30 Days)
- CHI 186.2K
- VIR 1.2M
- Earning Date
- CHI 01-01-0001
- VIR 08-04-2025
- Dividend Yield
- CHI 9.90%
- VIR N/A
- EPS Growth
- CHI N/A
- VIR N/A
- EPS
- CHI N/A
- VIR N/A
- Revenue
- CHI N/A
- VIR $20,861,000.00
- Revenue This Year
- CHI N/A
- VIR N/A
- Revenue Next Year
- CHI N/A
- VIR $0.62
- P/E Ratio
- CHI N/A
- VIR N/A
- Revenue Growth
- CHI N/A
- VIR N/A
- 52 Week Low
- CHI $9.70
- VIR $4.32
- 52 Week High
- CHI $11.61
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- CHI 52.98
- VIR 54.74
- Support Level
- CHI $10.30
- VIR $5.31
- Resistance Level
- CHI $10.61
- VIR $5.92
- Average True Range (ATR)
- CHI 0.10
- VIR 0.30
- MACD
- CHI -0.01
- VIR 0.02
- Stochastic Oscillator
- CHI 45.16
- VIR 43.69
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.